The Next-Generation Immunotherapy Platform in Oncology
Powered by AI & Synthetic DNA, Odimma Therapeutics is building scalable personalized immunotherapies designed to transform how cancer is treated.
The Next-Generation Immunotherapy Platform in Oncology
_________
Powered by AI & Synthetic DNA, Odimma Therapeutics is building scalable personalized immunotherapies designed to transform how cancer is treated.
Personalized
Neoantigen Platform
Strategic Manufacturing Partnerships
CTA Submission
Progression
Oncology + Emerging Disease Potential
France 2030
Supported
Seed Financing
Completed
Personalized
Neoantigen Platform
Strategic Manufacturing
Partnerships
CTA Submission
Progression
Oncology + Emerging Disease Potential
France 2030
Supported
Seed Financing
Completed
The Odimma Platform
——————————————————
Why Odimma
Odimma Therapeutics is developing next-generation personalized immunotherapies powered by AI-driven neoantigen selection and synthetic DNA technology — designed to make precision oncology more scalable, adaptable and clinically actionable.
By combining computational biology, synthetic DNA manufacturing and immune activation strategies, Odimma is building a platform approach designed for the future of personalized cancer treatment.
Designed to expand the future of personalized treatment.
The Odimma Platform
——————————————————
Why Odimma
Odimma Therapeutics is developing next-generation personalized immunotherapies powered by AI-driven neoantigen selection and synthetic DNA technology — designed to make precision oncology more scalable, adaptable and clinically actionable.
By combining computational biology, synthetic DNA manufacturing and immune activation strategies, Odimma is building a platform approach designed for the future of personalized cancer treatment.
Designed to expand the future of personalized treatment.
01
__
AI Powered
Neoantigen Selection
AI-driven identification of personalized neoantigen targets designed to support precision immune activation.
02
__
Synthetic DNA Manufacturing
Synthetic DNA approach supporting scalable and flexible therapeutic manufacturing.
03
__
Personalized
by Design
Patient-specific therapeutic strategies designed for complex tumor environments.
04
__
Scalable Platform Architecture
A modular oncology platform designed for future therapeutic expansion.
01
__
AI Powered
Neoantigen Selection
AI-driven identification of personalized neoantigen targets designed to support precision immune activation.
02
__
Synthetic DNA Manufacturing
Synthetic DNA approach supporting scalable and flexible therapeutic manufacturing.
03
__
Personalized
by Design
Patient-specific therapeutic strategies designed for complex tumor environments.
04
__
Scalable Platform Architecture
A modular oncology platform designed for future therapeutic expansion.
Lead clinical program
——————————————————
ODI-2001
Personalized Immunotherapy Platform Candidate
ODI-2001 is Odimma Therapeutics’ lead oncology program, designed to combine AI-driven neoantigen selection, synthetic DNA technologies and personalized immune activation strategies for next-generation precision oncology.
To deliver neoantigens within a highly immunogenic context, personalized DNA is formulated with immune activation components, including MVA and anti-CTLA4, designed to induce and amplify anti-tumor immune responses.
Built as the first expression of the Odimma platform, ODI-2001 is designed to support scalable and adaptable personalized cancer treatment approaches.
Lead clinical program
——————————————————
ODI-2001
Personalized Immunotherapy Platform Candidate
ODI-2001 is Odimma Therapeutics’ lead oncology program, designed to combine AI-driven neoantigen selection, synthetic DNA technologies and personalized immune activation strategies for next-generation precision oncology.
To deliver neoantigens within a highly immunogenic context, personalized DNA is formulated with immune activation components, including MVA and anti-CTLA4, designed to induce and amplify anti-tumor immune responses.
Built as the first expression of the Odimma platform, ODI-2001 is designed to support scalable and adaptable personalized cancer treatment approaches.
our partners
——————————————————
Built Through
Strategic Partnerships
Odimma Therapeutics collaborates with leading biotechnology, genomic sequencing, manufacturing and clinical organizations to support the development of scalable personalized immunotherapy platforms.
TECHNOLOGY & MANUFACTURING partners
————————————————————————————————————————————————————
Synthetic DNA Manufacturing
Neoantigen Prediction
Tumor Sequencing
MVA Viral Component
ECOSYSTEM & INNOVATION SUPPORT
————————————————————————————————————————————————————
Supported by a growing network of biotechnology, manufacturing, clinical and innovation partners across Europe.
our partners
—————————————————
Built Through
Strategic Partnerships
Odimma Therapeutics collaborates with leading biotechnology, genomic sequencing, manufacturing and clinical organizations to support the development of scalable personalized immunotherapy platforms.
TECHNOLOGY & MANUFACTURING partners
——————————————————
Synthetic DNA Manufacturing
Neoantigen
Prediction
Tumor
Sequencing
MVA Viral Component
ECOSYSTEM
& INNOVATION SUPPORT
—————————————————
Supported by a growing network of institutional partners across Europe.
company
——————————————————
Building the Future of Precision Oncology
Odimma Therapeutics believes in the future of precision medicine and is developing next-generation personalized immunotherapy platforms designed to address some of the most difficult-to-treat cancers.
By combining advances in immuno-oncology, AI-driven neoantigen selection and synthetic DNA technologies, Odimma is building scalable therapeutic approaches for the next era of personalized cancer treatment.
Jean-Marc Limacher, MD
Chairman, Co-Founder, CMO
Medical Oncologist & Cancer Geneticist
company
——————————————————
Building the Future of Precision Oncology
Odimma Therapeutics believes in the future of precision medicine and is developing next-generation personalized immunotherapy platforms designed to address some of the most difficult-to-treat cancers.
By combining advances in immuno-oncology, AI-driven neoantigen selection and synthetic DNA technologies, Odimma is building scalable therapeutic approaches for the next era of personalized cancer treatment.
Jean-Marc Limacher, MD
Chairman, Co-Founder, CMO
Medical Oncologist & Cancer Geneticist
From the Newsroom
Key milestones, partnerships and scientific advances shaping our journey
ONCOLOGY • CORPORATE
____
ODI-2001 Pharmaceutical Process Approved, Validated and Ready for Clinical Deployment
A major regulatory milestone brings ODI-2001 one step closer to delivering a new generation of personalized immunotherapy to patients.
From the Newsroom
Key milestones, partnerships and scientific advances shaping our journey
ONCOLOGY • CORPORATE
____
ODI-2001 Pharmaceutical Process Approved, Validated and Ready for Clinical Deployment
A major regulatory milestone brings ODI-2001 one step closer to delivering a new generation of personalized immunotherapy to patients.